Modulation of SERCA2a of Intra-Myocytic Calcium Trafficking in Cardiomyopathy Secondary to Duchenne Muscular Dystrophy
Phase 1
Not yet recruiting
- Conditions
- DMD-Associated Dilated Cardiomyopathy
- Interventions
- Genetic: SRD-001
- First Posted Date
- 2024-01-25
- Last Posted Date
- 2024-01-25
- Lead Sponsor
- Sardocor Corp.
- Target Recruit Count
- 12
- Registration Number
- NCT06224660
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Preserved Ejection Fraction
Phase 1
Recruiting
- Conditions
- Heart Failure, DiastolicHeart Failure With Preserved Ejection Fraction
- Interventions
- Biological: AAV1/SERCA2a
- First Posted Date
- 2023-09-29
- Last Posted Date
- 2023-09-29
- Lead Sponsor
- Sardocor Corp.
- Target Recruit Count
- 10
- Registration Number
- NCT06061549
- Locations
- ๐บ๐ธ
Duke University, Durham, North Carolina, United States
๐บ๐ธUniversity of Texas Southwestern Medical Center, Dallas, Texas, United States
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
Phase 1
Recruiting
- Conditions
- Congestive Heart FailureHeart Failure, SystolicHeart FailureHFrEF - Heart Failure With Reduced Ejection Fraction
- Interventions
- Biological: SRD-001Drug: Placebo
- First Posted Date
- 2021-01-11
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Sardocor Corp.
- Target Recruit Count
- 57
- Registration Number
- NCT04703842
- Locations
- ๐บ๐ธ
University of Texas Southwestern Medical Center, Dallas, Texas, United States
๐บ๐ธUniversity of Washington Medicine, Seattle, Washington, United States
๐บ๐ธSan Diego Cardiac Center, San Diego, California, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath